Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), is spectrum of diseases that ranges from non-alcoholic fatty liver (NAFL) to ...

∙ Presentation of results during the annual congress of the International Diabetes Federation in Abu Dhabi on December 5, 2017. LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: VALBIOTIS ...

Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a condition that affects billions worldwide. Their research has led to the ...

The unmet need in non-alcoholic steatohepatitis (NASH) is getting bigger and bigger. In the decade up to 2032, the number of diagnosed cases in seven major markets is forecast to grow by 4.5 million, ...

When left uncontrolled, fatty liver disease can progress to severe conditions, including non-alcoholic steatohepatitis (NASH) ...

For those dealing with fatty liver disease, there’s welcome news to report. Earlier this year, the United States Food and Drug Administration (FDA) approved the first and only fatty liver disease drug ...

NAFLD is a chronic liver disease caused by fat buildup in the liver, even with little to no alcohol use. Risk factors for NAFLD include being overweight or obese, having type 2 diabetes, high ...

Because omega-3 polyunsaturated fatty acids have been shown to reduce hepatic dysfunction in NASH, but the molecular underpinnings of this action were elusive, researchers conducted a multiomic ...

Excessive fructose intake from soft drinks is linked to liver damage and NAFLD. Lifestyle modifications are essential for ...